ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Relay raises $400 million to wrangle protein motion

by Lisa M. Jarvis
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

 

Relay Therapeutics, which aims to take down difficult cancer drug targets by combining computational methods with emerging lab tools, has raised a whopping $400 million in its third formal financing round. The privately held company says it is the biggest series C in biotech industry history. Relay plans to use the money to build its computational tools, expand its workforce from 70 people to 100, and put compounds in the clinic.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment